Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 344

Posts Tagged ‘research’

La democrazia esiste ancora?

Posted by fidest press agency su mercoledì, 11 dicembre 2019

La rabbia nei confronti dei poteri economici, le disuguaglianze crescenti e l’inquietudine per i rapidi cambiamenti tecnologici e climatici in atto hanno generato un clima di disaffezione nei confronti della democrazia. Secondo un sondaggio di Pew Research, condotto in 27 Paesi nel mondo, il 51% dei cittadini non è più soddisfatto del funzionamento delle istituzioni democratiche. Nelle democrazie di tutto il mondo, si legge su Project Syndicate, gli elettori hanno sempre più la sensazione che la maggior parte delle decisioni che incidono sulle loro vite in realtà vengano prese altrove. Nonostante i dati dicano che la democrazia sia in netto vantaggio rispetto ai regimi autoritari (Ourworldindata), “la democrazia oggi sta combattendo per la sua stessa sopravvivenza”, avverte Foreign Policy. Negli ultimi mesi, le proteste di piazza hanno coinvolto sia i Paesi ricchi sia quelli poveri, sia le democrazie forti sia i regimi più repressivi. Al centro di questa rabbia c’è la diffusa percezione che i governi agiscano nell’interesse delle élite piuttosto che delle persone. Il che solleva una questione: la democrazia è ancora la migliore forma di governo? (Ekathimerini). Tra innovazione e regressione – Già nel 2007 lo storico Eric Hobsbawm si interrogava sulla capacità della democrazia di fronteggiare dinamiche complesse e travolgenti come la globalizzazione e il terrorismo (Globalisation, democracy and terrorism). Oggi la finanziarizzazione, le trasformazioni del mondo produttivo e la comparsa di nuove potenze di chiaro stampo non democratico mettono ancora più in crisi l’impianto liberale nato nell’Ottocento e legato al primo e al secondo decollo industriale scrive Altreconomia. L’aspetto paradossale – osserva Nadia Urbinati nella sua Introduzione al nuovo Annale di Fondazione Feltrinelli intitolato Thinking Democracy Now: Between Innovation and Regression – è che l’ideologia democratica non è affatto messa in discussione: la democrazia oggi gode di un’indiscussa egemonia, al punto che anche chi la mette a repentaglio e ne mina le fondamenta lo fa in suo nome, promettendo di accrescerla e coniando espressioni ossimoriche come “democrazia illiberale”.

Posted in Spazio aperto/open space | Contrassegnato da tag: , , | Leave a Comment »

Hyperfine Research Inc. Teams with NVIDIA on Next-Generation Point-of-Care MRI System

Posted by fidest press agency su mercoledì, 4 dicembre 2019

Hyperfine Research, Inc. is demonstrating the world’s first bedside, portable, point-of-care MRI (POCMRI) system at the 2019 Radiological Society of North America (RSNA) annual meeting. The Hyperfine POCMRI is ultra-compact, standing 3 feet wide and 5 feet tall, and is currently 510(k) submitted for clinical brain imaging. The key to the Hyperfine POCMRI is the ability to use ordinary permanent magnets, which require no power or cooling, to produce an MR image. Hyperfine’s goal is to produce images that provide significant clinical value. Hyperfine is collaborating with top-tier partners to evaluate the clinical utility and efficacy of POCMRI.The Hyperfine POCMRI can operate in an open environment and requires no special shielding. This means that the Hyperfine POCMRI can conduct MRI in electromagnetically noisy environments — in hospitals and beyond. MRI has no associated cancer risk, and the Hyperfine POCMRI produces no ionizing radiation. Instead, the Hyperfine POCMRI uses ultra-low magnetic fields and low-power radio waves to do imaging of the brain and other body parts. Early clinical results show that the Hyperfine POCMRI can image brain disease and brain injury using scans that are about 5-10 minutes long.
Critical to POCMRI is advanced computing. Since the very first MRI of a human subject, computing power has increased a billion times relative to cost. Hyperfine is using GPU computing to enable clinical MRI with 20-40 times less magnetic field than that of current standard-of-care hospital MRI. Lower magnetic field means lower power requirements; the POCMRI requires only a standard electrical power outlet for operation. Lower magnetic field also means less weight. The POCMRI sits on a motorized drive and can be wheeled from hospital bed to hospital bed and be taken up and down standard elevators.Hyperfine was founded by Jonathan M. Rothberg, PhD, founder of Butterfly Network, Inc. Hyperfine has chosen to partner with NVIDIA Corporation to help implement next-generation MRI computing architecture. NVIDIA is the leader in artificial intelligence hardware and software across cloud, edge, and now embedded platforms.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

The American Association for Cancer Research Conference

Posted by fidest press agency su sabato, 23 novembre 2019

Omeros Corporation (Nasdaq: OMER) presented new GPR174 immuno-oncology data yesterday at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy in Boston, Massachusetts. The positively received and well-attended presentation about the company’s cell-based and animal studies related to its newly discovered cancer immunity axis was made by Marc Gavin, Ph.D., Omeros’ Director of Immunology. This data can now be accessed on the company’s website at https://investor.omeros.com/presentations. Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros has multiple Phase 3 and Phase 2 clinical-stage development programs focused on complement-mediated disorders and substance abuse, as well as a diverse group of preclinical programs including GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros’ proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating platform.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Engitix Receives a Golden Ticket to LabCentral from Takeda to Advance Fibrosis and Solid Tumour Research

Posted by fidest press agency su venerdì, 8 novembre 2019

Engitix Ltd (‘Engitix’), a private company focused on drug discovery for fibrosis and solid tumours based on its pioneering human extracellular matrix (ECM) platform, announced that its subsidiary Engitix, Inc, has been awarded a Golden Ticket to LabCentral by Takeda Pharmaceutical Company Limited (Takeda). The Golden Ticket provides Engitix one year of lab bench space at LabCentral, a world-class shared laboratory and office space in Cambridge, Massachusetts. It includes access to LabCentral’s shared infrastructure and services, such as first-class lab, facility, and administrative support, skilled laboratory personnel, and participation in LabCentral’s training programme and seminars. Engitix will use the Golden Ticket to advance its human extracellular matrix (ECM) research in fibrosis and solid tumours disease progression.
“We are honoured to have received this Golden Ticket from Takeda, bringing us immediate access to a world-class bioresearch facility. It is a first step in developing Engitix’s presence in the United States and I look forward to building our network in Cambridge and across the USA more widely. We are also delighted that Takeda, a leader in the area of gastrointestinal diseases, has recognised the potential in Engitix’s ECM technology,” said Dr Giuseppe Mazza, Engitix co-founder and CEO.Engitix has developed the world’s first proprietary drug discovery platform based on tissue-specific and disease-specific human ECM scaffolds. The company’s 3D human ECM scaffolds provide an enabling tool for a better understanding of the role of the ECM in disease development and progression, leading to the identification of more relevant targets for drug discovery and biomarker development. A key current limitation in developing more effective treatments in fibrosis and for various solid cancers has been the absence of human ECM in experimental models. Engitix’s mission is to increase the quality of therapeutics targets selected for development and a reduction in the number of later-stage drug trial failures by establishing more advanced platforms for drug target identification and validation, in which healthy as well as diseased cells can be tested with potential therapeutic agents within their natural physiological and pathological microenvironment.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Inaugural TechVision Research Conference

Posted by fidest press agency su giovedì, 7 novembre 2019

Radiant Logic is proud to be a premier-level sponsor of Chrysalis, the first TechVision Research conference, happening November 11-14, 2019 in San Diego. The conference aims to address the most relevant, pressing challenges facing today’s digital enterprise based on an attendee-driven agenda. As the leading provider of the federated identity and directory service (FID), Radiant Logic looks forward to participating in conversations about simplifying, streamlining, and modernizing the way identity is managed in today’s Fortune 1000 enterprises.According to Gary Rowe, CEO and Founder of TechVision Research, “The goal of the conference is to improve the state of how the industry responds to the real needs of the enterprise; this is achieved by an honest discussion about the problems, future enterprise needs and designing the right path forward. We will work hard to educate, but also to get input, discuss issues, and work through solutions that provide attendees with practical insights and advice.” As a sponsor of this inaugural event, Radiant Logic is hosting a hospitality suite on the evening of Tuesday, November 12. In addition, Wade Ellery, Senior Solutions Architect at Radiant Logic, will present on a panel titled “Putting the IAM Pieces Together; Standards and Integration.” This panel session describes the key standards, architectural elements, governance models and integration tools and approaches needed to extend/integrate existing services while transitioning the foundation for the future.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

2019 Wolfe Research Healthcare Conference

Posted by fidest press agency su venerdì, 25 ottobre 2019

New York City November 6 at 10:30 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Wolfe Research Healthcare Conference. A live webcast of the presentation will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at http://www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 30 days.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts are currently focused on the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), and hepatitis B virus (HBV).Enanta’s research and development activities are funded by royalties from HCV products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is now sold by AbbVie in numerous countries as part of its newest treatment for chronic hepatitis C virus (HCV) infection. This leading HCV regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). http://www.enanta.com for more information.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Nonprofit CureDuchenne Launches Biobank to Fuel Research for Duchenne Muscular Dystrophy

Posted by fidest press agency su martedì, 15 ottobre 2019

CureDuchenne, a global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy (Duchenne), announced today it has initiated the development of a biobank for Duchenne. The CureDuchenne Biobank is dedicated to empowering Duchenne research and the search for a cure for Duchenne that is independent and accessible to all researchers.In partnership with Dr. Tahseen Mozaffar of the University of California, Irvine (UCI) for strategic development and implementation, and with RUDER Infinite Biologics (RUCDR), the world’s largest university-based biorepository, for biobanking services, the CureDuchenne Biobank plans to begin sample collecting immediately at CureDuchenne Cares events around the country.“CureDuchenne is committed to supporting projects that could lead to a cure for Duchenne. But with limited resources to conduct research, scientists at academic institutions, biotechnology and pharmaceutical companies are not able to conduct the work necessary to find a cure for every child with Duchenne,” said Debra Miller, founder and CEO, CureDuchenne. “To fill that gap, it’s important to provide researchers with free and unrestricted access to the cell lines they need for Duchenne research,” Miller added. “Advances in precision medicine rely on open access biobanks with human biological specimens for analysis with the latest technologies long after the time of their collection,” said Dr. Andrew Brooks, chief operating officer, RUDCR Infinite Biologics. “We are thrilled to add Duchenne to the growing list of biobanks to help cure genetic diseases like Duchenne,” Dr. Brooks added.Minimally invasive blood and skin tissue samples will be requested on a voluntary basis from patients and, if possible, from their unaffected immediate blood relatives (parents, siblings or adult children) who may be interested in supporting scientific studies. To help ensure that Duchenne patients from all population groups can potentially benefit from the research, Duchenne patients from diverse age ranges, ambulatory status, genetic mutations and racial, cultural and socioeconomic groups are strongly encouraged to participate in this initiative.By donating specimen to the dedicated CureDuchenne Biobank, families will: enable the development of patient cell lines specialized to their child’s gene mutation that can be used by any researcher to develop customized treatments; contribute to genetic studies to understand how any of the mutations in the body affect disease progression and response to therapies; and contribute to research investigating how to harness the immune response to allow for more effective treatment.The proposed CureDuchenne Biobank board will consist of experts in biorepositories and registries, technology transfer, genetics, neuromuscular disease, immunology and ethical, legal and social issues. Dr. Tahseen Mozaffar and Dr. Armando Villalta, assistant professor, Department of Physiology & Biophysics, UCI School of Medicine are leading the CureDuchenne Biobank board. Together with CureDuchenne executives, the governing board will determine access to the CureDuchenne Biobank collection. Deidentified data and samples will be released to approved researchers in Duchenne.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Update on the research operations of the Bourbon Rhode crew

Posted by fidest press agency su martedì, 8 ottobre 2019

Several vessels have continued to survey the search area today, with no results for the past 4 days. The CROSS has decided to make the search operation evolve. It will regularly disseminate messages to vessels in the shipwreck zone and ask them to carry out adapted watch.”BOURBON and all its employees are in mourning today and I would like to reiterate our sincere condolences and our full support to the families and loved ones of the victims. We are working in close cooperation with the various stakeholders to understand the facts and circumstances of this tragedy. Finally, we thank the entire maritime community for its many signs of solidarity, so precious in these difficult times. I would like to reiterate our heartfelt thanks to the CROSS teams, the crews of the French Navy and the commercial vessels involved in search operations,” BOURBON Corporation CEO Gael Bodénès declared.
Among the market leaders in marine services for offshore oil & gas, BOURBON offers the most demanding oil & gas companies a wide range of marine services, both surface and sub-surface, for offshore oil & gas fields and wind farms. These extensive services rely on a broad range of the latest-generation vessels and the expertise of more than 8,200 skilled employees. Through its 31 operating subsidiaries the group provides local services as close as possible to customers and their operations throughout the world, of the highest standards of service and safety.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

8th Annual Research Conference

Posted by fidest press agency su martedì, 1 ottobre 2019

OptionMetrics, an options database and analytics provider for international institutional investors and academic researchers, is announcing Dean Curnutt, Founder and CEO of Macro Risk Advisors, will keynote its 8th Annual Research Conference (ORC2019), Monday, October 28, at Fordham University, New York City. To provide perspective on the current market, Curnutt will provide a retrospective look at some of the largest blow-ups in the derivatives market, what happened, and why, in his talk, “Steroids, Credit Growth and the Derivatives Blow Up Hall of Fame.”Under Curnutt’s leadership, Macro Risk Advisors has become the highest ranked boutique in the Tabb Group Survey of Option Research providers and offers in-depth global market risk analysis and transaction execution services. Curnutt formerly was managing director and head of equity sales-trading at Banc of America Securities. A recognized expert on risk and cross-asset volatility, he frequently appears on Bloomberg TV to share his views on markets and has delivered keynote presentations at the CBOE Risk Management Conference. Curnutt was named a “Rising Star of Hedge Funds” by Institutional Investor. He is an adjunct professor of finance and a member of the Board of Governors at St. John’s University.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Cancer Research Project Funded by Massachusetts Life Sciences Center Grant

Posted by fidest press agency su venerdì, 13 settembre 2019

Digital Health Impact – Aimed at offering more effective drugs at a lower cost to cancer patients turning to photomedicine as an alternative to chemotherapy, a grant from the Massachusetts Life Sciences Center (MLSC) will have chemical and data scientists working side by side at the Lopez Lab of Boston’s Northeastern University and the Cambridge facilities of Kebotix, an artificial intelligence technology company for new chemicals and materials.
“What makes this grant different from many others is it’s bringing industry and academics closer together, while importing top data scientists to Massachusetts to work on today’s most pressing life science problems,” said Dr. Steven Lopez, assistant professor of chemistry at Northeastern University.The project was among several announced today at Digital Health Impact 2019, a summit hosted by the Massachusetts Biotechnology Council that explores how life sciences companies may capitalize on the power of data and digital technologies in transforming drug development, discovery and patient care.Lopez’s research team uses high-throughput quantum mechanical computation to identify next-generation organic materials for applications in renewable energy and photomedicine. The results of these computations are open-access via Lopez’s website (web.northeastern.edu/lopezlab/verdedb). Partnering with Kebotix and its self-driving lab, the world’s first for materials discovery powered by machine learning algorithms for decision making and robots for synthesis and characterization, the Lopez Lab is expected to drastically accelerate development of multicolor chromophores used in cancer surgery and light-activated therapy.The partnership provides Northeastern University access to Kebotix’s autonomous lab capabilities and the team’s expertise in machine learning of materials properties.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

“Global Clinical Research Services – Procurement Market Intelligence Report”

Posted by fidest press agency su venerdì, 13 settembre 2019

The spend momentum for this market is attributed to the increase in R&D expenditure to cater to the pressing requirement for new drugs and devices in emerging countries such as India, China, Brazil, and Argentina. Prevalence of chronic diseases and the aging demography will create demand for newer and better drugs in these countries.This report provides actionable insights to improve source-to-contract cycle performance in the Global Clinical Research Services Market. It helps sourcing professionals formulate better category strategies, enhance savings, understand supplier and market challenges, and implement sourcing best practices.
The report provides up-to-date information about market shifts and potential risks, as well as in-depth knowledge of products and services, which can help in planning and in executing category management activities. It focuses on the cost-saving aspects of procurement and on providing insights that can lead to optimization of category spend.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Global Central Nervous System Diseases Drug Delivery Research Report 2019

Posted by fidest press agency su giovedì, 15 agosto 2019

The “Drug Delivery in Central Nervous System Diseases – Technologies, Markets & Companies” report from Jain PharmaBiotech has been added to Research AndMarkets. com’s offering. The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders. Drugs may be administered directly into the CNS or administered systematically (e.g., by intravenous injection) for targeted action in the CNS. The major challenge to CNS drug delivery is the blood-brain barrier (BBB), which limits the access of drugs to the brain substance.Advances in understanding of the cell biology of the BBB have opened new avenues and possibilities for improved drug delivery to the CNS. Several carrier or transport systems, enzymes, and receptors that control the penetration of molecules have been identified in the BBB endothelium. Receptor-mediated transcytosis can transport peptides and proteins across the BBB. Methods are available to assess the BBB permeability of drugs at the discovery stage to avoid development of drugs that fail to reach their target site of action in the CNS.Various strategies that have been used for manipulating the blood-brain barrier for drug delivery to the brain include osmotic and chemical opening of the blood-brain barrier as well as the use of transport/carrier systems. Other strategies for drug delivery to the brain involve bypassing the BBB. Various pharmacological agents have been used to open the BBB and direct invasive methods can introduce therapeutic agents into the brain substance.It is important to consider not only the net delivery of the agent to the CNS, but also the ability of the agent to access the relevant target site within the CNS. Various routes of administration as well as conjugations of drugs, e.g., with liposomes and nanoparticles, are considered. Some routes of direct administration to the brain are non-invasive such as transnasal route whereas others involve entry into the CNS by devices and needles such as in case of intrathecal and intracerebroventricular delivery.
Systemic therapy by oral and parenteral routes is considered along with sustained and controlled release to optimize the CNS action of drugs. Among the three main approaches to drug delivery to the CNS – systemic administration, injection into CSF pathways, and direct injection into the brain – the greatest developments is anticipated to occur in the area of targeted delivery by systemic administration.Many of the new developments in the treatment of neurological disorders will be biological therapies and these will require innovative methods for delivery. Cell, gene and antisense therapies are not only innovative treatments for CNS disorders but also involve sophisticated delivery methods. RNA interference (RNAi) as a form of antisense therapy is also described.The role of drug delivery is depicted in the background of various therapies for neurological diseases including drugs in development and the role of special delivery preparations. Pain is included as it is considered to be a neurological disorder. A special chapter is devoted to drug delivery for brain tumors. Cell and gene therapies will play an important role in the treatment of neurological disorders in the future.The method of delivery of a drug to the CNS has an impact on the drug’s commercial potential. The market for CNS drug delivery technologies is directly linked to the CNS drug market. Values are calculated for the total CNS market and the share of drug delivery technologies. Starting with the market values for the year 2017, projections are made to the years 2023 and 2028.The markets values are tabulated according to therapeutic areas, technologies and geographical areas. Unmet needs for further development in CNS drug delivery technologies are identified according to the important methods of delivery of therapeutic substances to the CNS. Finally suggestions are made for strategies to expand CNS delivery markets. Besides development of new products, these include application of innovative methods of delivery to older drugs to improve their action and extend their patent life.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Telix Pharmaceuticals and German Cancer Research Center

Posted by fidest press agency su martedì, 6 agosto 2019

MELBOURNE, Australia and HEIDELBERG, Germany (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has entered into a collaboration agreement with the German Cancer Research Center (Deutsches Krebsforschungszentrum or DKFZ) in the field of image-guided surgery for prostate cancer.
Researchers at DKFZ and Heidelberg University Clinic have developed a next-generation radiotracer based on 68Ga-PSMA-11 (currently under development by Telix as TLX591-CDx, marketed as illumetTM in the United States) that incorporates a fluorophore (a fluorescing agent) in addition to the ability to molecularly-target radiation for imaging with Positron Emission Tomography (PET). The result is a technology that can simultaneously image prostate cancer with PET as well as provide intra-operative surgical guidance through fluorescence (optical) imaging. Image-guided (fluorescence) imaging is a standard embedded feature of modern robotic surgery platforms (e.g. the Firefly® imaging system as part of the da Vinci® surgical robotics system by Intuitive Surgical), extensively used in urologic surgery worldwide.Under the terms of the collaboration, Telix will collaborate with DKFZ and affiliated researchers to conduct the necessary translational research studies to evaluate the technology in the surgical setting. The agreement includes a fully negotiated, exclusive option to license the technology for commercial development. The principal investigator at DKFZ, Dr. Ann-Christin Baranski, and who is also a scientist of the German Cancer Consortium (DKTK, partner location Freiburg) and the department of Nuclear Medicine (University Hospital Freiburg) added, “Our colleagues at Telix have made tremendous progress in commercializing PSMA-11 PET imaging, a technology that was originally developed here at DKFZ. To this end, Telix we feel Telix is an appropriate commercial partner for this novel technology and we look forward to working with the Telix team to evaluate the impact of this technology in patients in the near future.”

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Columbia Threadneedle Investments annuncia la nomina di un nuovo Senior Research Director

Posted by fidest press agency su martedì, 30 luglio 2019

Columbia Threadneedle Investments (Columbia Threadneedle), uno dei principali gruppi di risparmio gestito a livello globale, consolida ulteriormente il suo team di Investment Solutions globale con l’ingresso di Stuart Jarvis in qualità di Senior Research Director. Stuart, che sarà basato a Londra e riporterà a Lorenzo Garcia, responsabile EMEA e APAC Investment Solutions, vanta oltre 20 anni di primaria esperienza nella analisi attuariale e degli investimenti.Stuart negli ultimi 15 anni ha lavorato presso BlackRock, dove nell’ultimo periodo è arrivato a essere Managing Director del Portfolio Research Group all’interno della unit BlackRock Investment Institute. Prima ancora è stato responsabile della divisione di allocazione di portafogli e ricerca legata alle varie ipotesi di scenari dei mercati finanziari, nonché della modellizzazione di soluzioni personalizzate per piani pensionistici, banche centrali e fondi sovrani. Prima di questi ruoli, Stuart ha dato un importante valore aggiunto nella creazione, all’interno di BlackRock, della Unit di Liability Driven Investments. Ha iniziato il suo percorso professionale presso Hewitt Bacon & Woodrow (ora Aon Hewitt) in qualità di consulente in materia di fondi pensione. È membro dell’Institute of Actuaries e ha conseguito più lauree in matematica presso l’Università di Cambridge e l’Università di Oxford. È un esperto pluri-riconosciuto nel campo della modellistica stocastica e dell’asset allocation.Il team Global Investment Solutions di Columbia Threadneedle si occupa in particolare di tutte le attività di ricerca, progettazione e realizzazione di soluzioni di investimento personalizzate per tutti quei clienti che possono così avvantaggiarsi di una esperienza molto ampia di gestione degli investimenti attivi e di una consolidata capacità di ricerca multi-manager. Il Gruppo è riconosciuto, infatti, per avere una eccellente expertise nella costruzione di soluzioni altamente personalizzate e rivolte a clienti istituzionali.Lorenzo Garcia, Responsabile Investment Solutions EMEA e APAC di Columbia Threadneedle Investments commenta così la nuova nomina: “Il business di Investment Solutions è una semrpe più consolidata eccellenza di Columbia Threadneedle a livello globale. I clienti hanno costantemente bisogno di soluzioni di investimento cucite su misura in base alle proprie specifiche esigenze. L’ingresso di Stuart nel nostro team e la sua grande esperienza porteranno un sicuro valore aggiunto utile a consolidare ulteriormente la nostra attività di modellizzazione di asset-liability e ci aiuteranno a fornire soluzioni avanzate e sempre più personalizzate per risolvere le esigenze anche più complesse dei nostri clienti”.www.columbiathreadneedle.com

Posted in Economia/Economy/finance/business/technology | Contrassegnato da tag: , , | Leave a Comment »

World-Class Research Center Opens in Palo Alto

Posted by fidest press agency su mercoledì, 10 luglio 2019

NTT Research, Inc. (“NTT Research”), a subsidiary of Nippon Telegraph and Telephone Corporation (TYO:9432, “NTT”), today announced it has commenced operations as a global effort that will be directed by world-class scientists in Palo Alto, CA. The three areas of initial focus will be quantum computing; cryptography and information security; and medical and health informatics. A grand opening ceremony, hosted by NTT President and CEO Jun Sawada, will take place today Monday, July 8, at Rosewood Sand Hill in Menlo Park.
NTT Fellow Tatsuaki Okamoto to be appointed director of NTT CIS Laboratories, Cryptography & Information Security. Dr. Okamoto is an internationally acclaimed cryptography scientist, recognized for his work in third-generation cryptosystems and the promotion of a trustworthy digital society. He has also held positions at NTT Yokosuka Electrical Communication Labs, the University of Tokyo, the University of Waterloo (Canada), AT&T Bell Labs, Tsukuba University and Kyoto University.
Professor Hitonobu Tomoike to be appointed director of NTT MEI Laboratories, Medical Health Informatics. Professor Tomoike conducts research into precision medicine, based on bio-sensors and analytics. He is an Advisor to and former Director of the Sakakibara Heart Institute and Fellow of the American College of Cardiology and American Heart Association. He has also held positions at UCSD, Kyushu University, Yamagata University, and the National Cerebral and Cardiovascular Center (Osaka).
In addition to hiring outstanding researchers in each of these fields, NTT Research will foster collaborations with top research institutions, engage in joint research projects, and host visiting scholars and post-doctoral fellows. Among its first Distinguished Scientists is cryptographer Brent Waters, a professor at the University of Texas at Austin and recipient of the Association for Computing Machinery (ACM) Computer and Communications Security (CCS) Test-of-Time and Grace Hopper Awards. The center opens today with a team of 15 researchers, a number which is expected to grow to 50 over the next few years.
The formal launch of NTT Research will occur at a grand opening ceremony today, July 8, from 3:00 – 6:30 p.m. PDT, at Rosewood Sand Hill, a hotel and retreat in Menlo Park. Mr. Sawada will host the event, which will include a media briefing, opening reception, keynotes by NTT Research scientists, exhibits, and a performance by the internationally renowned violinist Ryu Goto (Physics B.A., Harvard).
The longer-term plans for NTT Research include expansion. After launching and staffing up in Silicon Valley, home to the largest number of papers submitted in the fields of quantum computing, cryptography and medical informatics, NTT Research expects to open additional offices in Boston, Munich, Israel and London. Through these global laboratories, NTT will build a world-class network of scientists engaged in fundamental and high-impact research.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Global Credit Specialist CIFC Completes Initial UK Research Team Hires

Posted by fidest press agency su mercoledì, 3 luglio 2019

Global credit specialist CIFC, which launched a European office in London last year, has completed the first phase of its UK research team recruitment with the appointment of its fourth analyst.Senior Analyst Rinse Terpstra has joined from Chenavari Investment Managers where he worked as a senior investment analyst focusing on CLOs. He has more than 12 years of leveraged loan and high yield credit experience in Western and Central Eastern Europe as well as Turkey.Analyst Zoltan Paller has joined from UBS where he focused on leveraged finance and direct lending opportunities in the EMEA region. Prior to UBS, he held positions in the Corporate Credit team of Morgan Stanley in Budapest and Fitch in London.
Analyst Max Elliott-Taylor has joined from Investcorp Credit Management in London where he was an associate in the credit research team investing in leveraged loans and high yield bonds for five years.Analyst Alessandro Garello Cantoni has joined from Bank of America Merrill Lynch where he worked for five years focusing on Italian and Iberian markets and later leveraged finance origination in the EMEA region.Their hires follow the recruitment last year of Managing Directors Joshua Hughes and Dan Robinson to open the London office and start building out the team.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Japan’s new molecular oncology clinical research

Posted by fidest press agency su giovedì, 20 giugno 2019

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QIAGEN Clinical Insight (QCI) offering was selected by the National Cancer Center of Japan, as part of the Japan’s Ministry of Health, Labour and Welfare’s precision medicine program, for the analysis, interpretation and reporting of molecular oncology and oncogenetic screening of cancer patients to contribute to the identification of targeted therapy treatment and clinical trial options.Japan’s Center for Cancer Genomics and Advanced Therapeutics (C-CAT), a unit within the National Cancer Center (NCC) of Japan, will use QIAGEN’s QCI platform including expert curated evidence knowledge bases, bioinformatics software and data center infrastructure to support the C-CAT’s molecular profiling services for core and cooperative hospitals of the country’s cancer genomic medicine program. QIAGEN has established an in-country data center in Tokyo, compliant with Japanese data security and privacy regulations, to support this national program.QCI is a cloud-based clinical decision support software platform used to generate actionable insights from next-generation sequencing (NGS) data. QCI leverages QIAGEN’s expert manually curated evidence knowledge base that includes more than 10 million biomedical findings and thereby be far represents the world’s largest commercial database of curated evidence data on somatic and inherited genetic variants. QCI-Interpret minimizes the complexity and cost of determining the significance of NGS data and automates guidelines for clinical actionability from leading oncology and pathology organizations.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Research reveals lack of common language in value transformation of U.S. health care

Posted by fidest press agency su mercoledì, 19 giugno 2019

Today’s U.S. health policy initiatives, including those from the Centers for Medicare & Medicaid Services, are aiming to derive more value from the health care dollar. This involves a shift from reimbursement based on volume to reimbursement based on the value of care delivered.With this shift comes a new set of terms being used across the industry, like value-based care and population health. Yet these terms have been found to hold different meanings for different stakeholders, and that has a variety of consequences for health care professionals, health care policymakers, patients, and payers, to name a few.
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, and Penn Medicine, set out to find consensus on three terms. Through the use of a Delphi research method that convenes a panel of experts to arrive at a group opinion or decision, lead researcher Marilyn Schapira, MD, MPH, led the panel through multiple rounds of surveys to achieve broadly applicable definitions for three terms: value-based care, value-based payment, and population health.After more than six months, the Delphi panel reached consensus on the term value-based payment but, after three rounds of ratings, was unable to arrive at a consensus definition for value-based care and population health, though distinct areas of agreement and disagreement were made clear. These findings were presented June 3 at the AcademyHealth Annual Research meeting.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Marine Genetic Resources: Bridging policy, law, science and research and development

Posted by fidest press agency su mercoledì, 29 Mag 2019

Over 65% of the biomass in the ocean is made of plankton. Marine microbes bring services to our ecosystem and their genetic diversity is remarkable. Moreover, marine genetic resources (MGR) have enormous potential in fields such as pharmaceutical, bioremediation, cosmetics, nutraceutical, or biomedical innovation.
MGR in areas beyond national jurisdiction are not regulated. Therefore, the European Commission organised an international workshop on “Marine genetic Resources in areas beyond national jurisdiction: bridging policy, law, science and research and development” on the 21st and 22nd of May in Brussels.Negotiators of the international treaty on marine biodiversity beyond national jurisdiction (BBNJ), top scientists, legal experts and representatives from the private sector and the civil society came together to better understand the scientific process related to the discovery, analysis and use of marine genetic resources (MGR) from areas beyond national jurisdiction, the high seas and the Area. In total, 90 participants from 32 countries. The workshop was an opportunity to bridge the world of the policy makers with the scientific community, legal experts and the private sector, for a better understanding of the scientific process related to the discovery, analysis and use of marine genetic resources (MGR) from areas beyond national jurisdiction, the high seas and its seabed.Participants had the opportunity to discuss important technical aspects related to: the sampling of MGR; their scientific analysis; their storing in collection; the transformation of samples into digital scientific information; examples of applied research; Legal issues , such as intellectual property rights (IPRs) were also high on the agenda.Molecular biologists described how DNA is extracted and transformed into digital data, which then needs to be curated before being analysed.The scientific community stressed the importance of having open access to data, as this is the foundation of scientific investigation. Oceanographers gave an overview of the technologies employed for sampling the deep sea and explained how difficult and costly it is to organise cruises in the high seas. International cooperation is therefore essential and there are plenty of good examples to follow. BBNJ negotiations is a political priority for the European Union. João AGUIAR MACHADO, Director General of DG MARE, stressed the importance in engaging with the scientific community and the private sector, with the support of the civil society organizations, in the ongoing negotiations.
The President of the BBNJ intergovernmental conference (IGC) at the UN, Rena Lee, underlined the need to base the negotiations on solid scientific knowledge and to look for practical solutions, through a pragmatic approach.

Posted in Estero/world news, Politica/Politics | Contrassegnato da tag: , , | Leave a Comment »

The new website of IDOS Research and Study Centre

Posted by fidest press agency su giovedì, 9 Mag 2019

From today the new website of IDOS Research and Study Centre, entirely renewed in its layout, contents and functions, is online. The website has been implemented thanks to the technical support of Lai Momo cooperative association, which for many years has been collaborating with IDOS to realize and promote the annual socio-statistical report on immigration in Italy, Dossier Statistico Immigrazione – Statistical Dossier
on Immigration, together with other publications and events. On the new website (www.dossierimmigrazione.it) everyone can find not only detailed information on all
events promoted by IDOS or where IDOS is called to intervene (meetings, conferences, seminars, courses, interviews and other training and/or sensitization activities), but also news and updates useful for operators and researchers, original reports edited by IDOS network of local researchers, press releases, socio-statistical tables and summaries, videos, graphics (all things that can be downloaded or pressed) concerning studies and publications annually edited by IDOS. What’s absolute new is that for the first time everyone can buy online all IDOS publications, both in paper format and – at a lower price – in digital format (pdf), through a fast, easy and sure online system of payment and invoice. In particolar, for every main annual report (Dossier Statistico Immigrazione – Statistical Dossier on Immigration, Osservatorio Romano sulle Migrazioni – Roman Observatory on Migrations, Rapporto Immigrazione e Imprenditoria – Report on Immigration and Entrepreneurship, etc.), it’s available for sale both the entire book and – separately purchasable in electronic format only – every single thematic chapter and the final addendum of statistical tables. Many other monographic publications, periodically edited by IDOS in collaboration with – or for commission of – some private or institutional bodies, are also available in addiction to such a rich archive of annual reports.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »